Cautious Optimism for AnaptysBio's ANB032: Promising Preclinical Data Amid Efficacy Uncertainties

TipRanksNov 27 00:36 ET

AnaptysBio, Inc.'s (NASDAQ:ANAB) 45% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Simply Wall StNov 16 09:09 ET

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Yahoo FinanceNov 16 08:15 ET

AnaptysBio Is Maintained at Overweight by JP Morgan

Dow JonesNov 12 10:51 ET · Ratings

Is AnaptysBio (NASDAQ:ANAB) Using Debt In A Risky Way?

Simply Wall StNov 12 07:39 ET

J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $66

Moomoo NewsNov 12 06:36 ET · Ratings